Abstract:Recent studies have established that metformin (MET), an oral anti‐diabetic drug, possesses antioxidant activity and is effective against different types of cancer in several carcinogen‐induced animal models and cell lines. In that, a study from our laboratory showed that MET protected against 7, 12‐dimethylbenz[a]anthracene (DMBA)‐induced breast carcinogenesis in vitro human non‐cancerous epithelial breast cells (MCF10A). However, whether MET can protect against breast cancer initiation in vivo rat model has not been reported before. Therefore, the overall objectives of the present study are to elucidate the potential chemopreventive effect of MET against DMBA‐induced rat breast carcinogenesis and explore the underlying mechanism involved, specifically the role of cytochrome P4501A1/1B1 pathway. In this regard, treatment of rat with DMBA (25 mg/kg) induced initiation of breast carcinogenesis in rat as evidenced by changes in biochemical and histopathological analysis. Importantly, the protective effect of MET against DMBA‐induced breast carcinogenesis was supported by the capability of MET (500 mg/kg) to restore the induction of the mRNA and protein expression levels of several DNA repair genes ( OGG1, XRCC1), and the level of 8‐hydroxy‐2‐deoxyguanosine (8‐OHdG), a DNA damage marker. In addition, MET was able to restore DMBA‐mediated changes in the gene expression of apoptotic (caspase‐3 and BAX) and inflammatory (TNF‐α and IL‐6) mediators. Interestingly, these changes were associated with proportional decrease in DMBA‐induced CYP1A1 and CYP1B1 gene expression. In conclusion, the present work provides the first evidence that MET protects against DMBA‐iduced rat breast carcinogenesis by inhibiting DNA adduct formation, inducing apoptosis and inhibiting the expression of CYP1A1/CYP1B1 pathway. Support or Funding Information This Project was funded by the National Plan for Science, Technology and Innovation (MAARIFAH), King Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia, Award Number (12‐MED3131‐02)

Metformin Protects against 7, 12‐Dimethylbenz[a]anthracene‐Induced Breast Cancer Initiation and Adduct Formation In Vivo Rat Model Through CYP1A1/CYP1B1 Pathway

Metformin Suppresses the Esophageal Carcinogenesis in Rats Treated with NMBzA Through Inhibiting AMPK/mTOR Signaling Pathway

Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis

Metformin reduces basal subpopulation and attenuates mammary epithelial cell stemness in FVB/N mice

Metformin as a Potential In Vitro Anticancer Modulator of Adenosine Monophosphate Kinase: A Review

Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling

Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways

Metformin Suppresses Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BL/KsJ-+Leprdb/+Leprdb Mice

Metformin protects against small intestine damage induced by diabetes and dunning's prostate cancer: A biochemical and histological study

Suppressive Effects of Metformin on Colorectal Adenoma Incidence and Malignant Progression

Tangeretin boosts the anticancer activity of metformin in breast cancer cells via curbing the energy production

Mechanism of metformin action in MCF-7 and MDA-MB-231 human breast cancer cells involves oxidative stress generation, DNA damage, and transforming growth factor β1 induction

Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects

Betulin ameliorates 7,12‐dimethylbenz(a)anthracene‐induced rat mammary cancer by modulating MAPK and AhR/Nrf‐2 signaling pathway

Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes

Metformin and Breast Cancer: Current Findings and Future Perspectives from Preclinical and Clinical Studies

Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization

Involvement of Catalase in the Protective Benefits of Metformin in Mice with Oxidative Liver Injury.

Assessing the anticancer effects of metformin

Metformin for cancer and aging prevention: is it a time to make the long story short?

Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines